Surgical interventions once disease progresses.

Provide better, more cohesive patient care with comanagement.

The goal of the inaugural International Keratoconus Academy (IKA) Keratoconus Symposium in Scottsdale, Arizona, was to help preserve vision.

Catch up on what happened in optometry during the week of May 22-May 26.

Instrumentation recreates properties of the myopic eye to test lenses that prevent visual decline.

As part of the American Diabetes Association's Health Equity Now program, the organization has partnered with Genentech, piloting a partnership within Alabama to specifically focusing on tackling barriers related to diabetic eye disease.

According to the company, the study has now reached its goal of 300 patients enrolled to evaluate ILUVIEN as a first line, baseline therapy for DME.

Artificial intelligence is the future of optometric disease monitoring.

The two companies have announced an exclusive agreement for Polifarma to commercialize AVT06, the proposed biosimilar to Eylea, in Turkey.

Growing evidence supports dual therapy to slow progression.

An epidemiologic study of myopia in a Chinese province found that economic status, gender, and age were associated with rates of myopia.

Diagnose, monitor, comanage—optometrists support patients throughout all stages of the disease.

This single-ingredient tear stabilizer from Bausch + Lomb and Novaliq could become the choice therapeutic for dry eye disease.

Both are critical to successful treatment, but how can optometrists help?

Catch up on what happened in optometry during the week of May 15-May 19.

Mitchell Jackson, MD, discussed laser scleral microporation from Ace Vision Group at the 2023 ASCRS annual meeting in San Diego.

Currently, there are several novel spectacle designs available across the world. Unfortunately, none of them are available in the US currently.

MIEBO, previously known as NOV03, is the first and only FDA-approved treatment for dry eye disease that targets tear evaporation.

John Berdahl, MD, discussed the Aurion clinical trials of endothelial cell therapy injection at the 2023 ASCRS annual meeting in San Diego.

Today, Alimera Sciences announced that they have acquired the US commercial rights of Yutiq (fluocinolone acetonide intravitreal insert) 0.18mg for the treatment of chronic non-infectious uveitis. Yutiq now joins Iluvien (fluocinolone acetonide intravitreal insert) 0.19 mg for DME in Alimera’s retina portfolio.